Please login to the form below

Not currently logged in
Email:
Password:

head and neck cancer

This page shows the latest head and neck cancer news and features for those working in and with pharma, biotech and healthcare.

BMS gets OK for monthly Opdivo dosing

BMS gets OK for monthly Opdivo dosing

cancer. It is competing in the marketplace with two other PD-1 inhibitors - Merck &Co/MSD’s Keytruda (pembrolizumab) and Roche’s Tecentriq (atezolizumab) - as well as PD-L1 inhibitors Imfinzi ... The new monthly injection can be used in a range of

Latest news

  • AZ bags key lung cancer approval for Imfinzi AZ bags key lung cancer approval for Imfinzi

    Before now Imfinzi was only approved for bladder cancer - where it has to compete head-to-head with other checkpoint inhibitors including Bristol-Myers Squibb’s Opdivo (nivolumab) and Merck ... AZ is also expecting read-outs from The KESTREL and EAGLE

  • Merck and Pfizer’s PD-L1 drug Bavencio flunks phase III trial Merck and Pfizer’s PD-L1 drug Bavencio flunks phase III trial

    That doesn’t alter the fact that gastric cancer is a big market opportunity, as the fifth most- common form of cancer, and could have added considerable momentum to Bavencio’s ... Opdivo failed a trial in first-line lung cancer, while Keytruda

  • Bad news for Innate Pharma as BMS-backed drug stumbles Bad news for Innate Pharma as BMS-backed drug stumbles

    additional benefit compared to Opdivo alone in patients with squamous cell carcinoma of the head and neck (SCCHN). ... and Innate indicated at the time that it was banking on positive results from the head and neck cancer study.

  • BMS’ Opdivo defies naysayers with healthy growth BMS’ Opdivo defies naysayers with healthy growth

    market. Growth has also come from a steady stream of new indications, including recent approvals in hepatocellular carcinoma, renal cell carcinoma and colorectal cancer. ... We are also looking forward to seeing data for Opdivo in first-line HCC and for

  • Merck, Pfizer cue up first EU launches for PD-L1 drug Bavencio Merck, Pfizer cue up first EU launches for PD-L1 drug Bavencio

    Germany and the UK will be the first to receive the skin cancer treatment. ... it introduced colorectal and head and neck cancer therapy Erbitux (cetuximab) more than a decade ago.

More from news
Approximately 6 fully matching, plus 91 partially matching documents found.

Latest Intelligence

  • Immunisation politicised Immunisation politicised

    sexually transmitted human papilloma virus (HPV), including strains that lead to cervical cancer. ... For example, the remarkable silence around the fact that some strains of HPV can also cause penile cancer, anal cancer, and cancer of the head and neck

  • Pharma deals in August 2015 Pharma deals in August 2015

    virus. INO-3112 generates killer T-cell responses to HPV 16 and 18 driven tumours and is in phase I / II clinical studies for cervical and head and neck cancers. ... Acquisition ‐ company. 847. Inovio. AZ/Medimmune. INO‐ 3112 vaccine in P1/2 for

  • Lonafarnib: promising results in first-ever trial for progeria Lonafarnib: promising results in first-ever trial for progeria

    Lonafarnib and tipifarnib are the most successful of the FTIs, currently in Phase II development for breast cancer, and acute myeloid leukaemia and glioma, respectively. ... Development in other oncological indications (chronic myeloid leukaemia,

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Mirna hires former Pfizer director as CMO Mirna hires former Pfizer director as CMO

    Prior to this, he was director of clinical oncology at Bristol-Myers Squibb where he worked on the clinical development of Erbitux (cetuximab), which is approved for colorectal cancer and head ... and neck cancer.

  • VentiRx appoints James Kyle Bryan as chief medical officer VentiRx appoints James Kyle Bryan as chief medical officer

    During his career, Dr Bryan has focused on drug discovery in oncology, and has a medical background in haematology and oncology. ... This experience will benefit VentiRx as it prepares to advance the development of VTX-2337 for patients with ovarian

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • A stumble, but not a fall – what’s next for Opdivo?

    In this manner, it can crucially target several cancers, a property that was successfully exploited by BMS and resulted in securing FDA nods for treating non-small cell lung cancer (NSCLC) ... Rubbing salt into BMS’ s wounds, Merck's  Keytruda snagged

  • ASCO 2015: What you missed in Chicago

    Specifically, we thought the checkpoint inhibitors in head and neck, lung cancer and melanoma really shone. ... Patel SP et al Mol Cancer Ther 2015[2] Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics